Obesity-associated nonalcoholic fatty liver disease (NAFLD) is highly prevalent, for which weight loss is the generally recommended clinical management. Low-carbohydrate ketogenic diets have been successful in promoting weight loss, but variations in the range of metabolic responses to these diets indicate that the effects of altering macronutrient content are not completely understood. This review focuses on the most recent findings that reveal the relationship between low-carbohydrate diets and NAFLD in rodent models and humans.
INTRODUCTION
The incidence of cardiovascular disease attributable to obesity, insulin resistance, and diabetes has markedly increased [1,2 & ]. Insulin resistance is highly correlated with ectopic lipid accumulation, particularly in the liver. Consequently, the pathogeneses of systemic insulin resistance and diabetes have been linked to nonalcoholic fatty liver disease (NAFLD). NAFLD is an independent predictor of cardiovascular disease -a stronger predictor than peripheral or visceral fat mass [3,4, 
& ]. A critical, but as yet only preliminarily defined influence over the development of NAFLD is distribution of macronutrient classes within the diet. Recently, attention has focused on the use of low-carbohydrate diets and their efficacy in controlling metabolic diseases including NAFLD [7] . However, although low-carbohydrate diets are effective for weight loss, seizure disorders, and potentially a host of other neurological diseases, determination of their relationships with metabolic responses, and fatty liver in particular, remains ongoing. As therapeutic application of low-carbohydrate diets is going to increase, deeper understanding of the range of metabolic responses observed, and the precise nutritional determinants of these responses, will be needed. The importance of further understanding the impact of low-carbohydrate diets is underscored by case reports of humans that reveal variations in the range of metabolic responses to these diets [8, 9] . This review examines the metabolic responses of rodents and humans to lowcarbohydrate diets, and will elucidate critical unanswered questions that merit follow-up preclinical and clinical evaluation.
The earliest stage of NAFLD is hepatic steatosis, which is defined by intrahepatic triglyceride (IHTG) concentrations exceeding 55 mg/g liver (5.5%), or when greater than 5% of hepatocytes harbor histological evidence of triglyceride storage [6 & ,10] . NAFLD prevalence is 15% in nonobese patients, but increases in obese (BMI 30.0-39.9 kg/m 2 ) and extremely obese (BMI !40.0 kg/m 2 ) patients to 65 and 85%, respectively. In addition to its association with systemic insulin resistance and adverse cardiovascular outcomes, NAFLD can progress to nonalcoholic steatohepatitis (NASH), which is characterized by steatosis and signs of hepatocyte injury, hepatic inflammation with collagen deposition, and elevation of serum alanine aminotransferase (ALT). Approximately 10-29% of patients with NASH will develop cirrhosis within 10 years, which can evolve to hepatocellular carcinoma. Informative reviews on the causes, stages, and implications of NAFLD have been published recently, but whether NASH can develop independently of a NAFLD stage remains to be fully explored [6 & ,10,11 & ]. Increased IHTG is caused by an imbalance between hepatocellular triglyceride formation and removal. Therefore, multiple hepatocyte pathways play roles, including rate of fatty acid uptake; esterification of fatty acids into, and lipolysis from, intracellular triacylglycerols (TAGs); rate of fatty acid oxidation (FAO); rate of TAG secretion as very low-density lipoproteins (VLDLs); and de-novo lipogenesis (DNL). Hepatic TAGs are synthesized from fatty acids that emanate from DNL, lipolysis of triglycerides stored in adipose tissue, and/or from diet-derived fats that are packaged as chylomicrons in intestinal enterocytes. A significant contributor to increased hepatic triglyceride content in NAFLD is increased DNL, in which increased hepatocellular carbohydrate is converted to fat. Muscle, and possibly adipocyte, insulin resistance may contribute to increased hepatocyte carbohydrate by diversion of glucose to the liver. In addition, magnetic resonance spectroscopy (MRS) of human livers recently revealed that patients with NAFLD exhibit augmented delivery of fatty acids, through increased peripheral lipolysis; elevated hepatocellular flux through the tricarboxylic acid (TCA) cycle; and increased gluconeogenesis, compared with NAFLDfree individuals [12 && ].
CLASSICAL DIET MODELS OF NONALCOHOLIC FATTY LIVER DISEASE
A detailed review of rodent dietary models of NAFLD has recently been published [13 & ]. Highcarbohydrate/low-fat, low-carbohydrate/high-fat, and high-carbohydrate/high-fat formulations have all been studied, as have the contributions of trans, monounsaturated, polyunsaturated, and chain length of fatty acids [14] [15] [16] [17] [18] . The role of nutritional methionine and choline contents are also important, because seminal rodent experiments have revealed molecular underpinnings of NAFLD pathogenesis using methionine and choline-deficient (MCD) diets. MCD diets commonly include high sucrose and fat contents, producing exuberant and rapid (within 2 weeks) NASH, particularly when carbohydrate content is highly enriched as either glucose or the particularly lipogenic monosaccharide fructose, as opposed to starch [19, 20, 21] . Despite robust IHTG and inflammation, MCD models do not exhibit systemic insulin resistance, and MCD diets induce a catabolic state that includes muscle wasting.
Choline is a major constituent of plasma and mitochondrial membranes, as well as the neurotransmitter acetylcholine, and is an essential nutrient that is particularly abundant in animal meats and eggs. The majority of choline is metabolized via either phosphorylation, to supply phospholipids for membrane synthesis, or oxidized and ultimately metabolized to S-adenosyl-L-methionine (SAM), a universal methyl donor [22] . The former pathway has been cited to support the notion that choline deficiency contributes to NAFLD by reducing VLDL packaging and secretion. However, choline deficiency also contributes to
KEY POINTS
Low-carbohydrate ketogenic diets are effective for weight loss, seizure disorders, and potentially a host of other neurological diseases.
Attention has focused on the use of low-carbohydrate diets and their efficacy in controlling metabolic diseases including obesity and NAFLD, but their relationships with metabolic responses are yet to be determined.
Ketogenic diet-fed mice ultimately develop NAFLD signatures and systemic glucose intolerance, but wholebody insulin responsiveness is not impaired.
Clinical and rodent research studies demonstrate a range of metabolic responses to low-carbohydrate diets, underscoring the importance of studying the metabolic effects of macronutrient and micronutrient dietary balance.
mitochondrial dysfunction, and therefore to FAO deficiencies, and has also been linked to increased fatty acid uptake. In a study conducted to understand the contributions of methionine and choline deficiency independently, mice were placed on a conventional MCD diet, versus methioninedeficient or choline-deficient diets. Over 2 weeks, the methionine-deficient diet reproduced many of the deleterious effects of the MCD diet including weight loss, hepatocellular injury, decreased mitochondrial SAM and glutathione, inflammation, and fibrosis, whereas choline deficiency caused only steatosis [23 & ].
KETONE METABOLISM AND LOW-CARBOHYDRATE (KETOGENIC) DIETS
The liver is a major destination for fatty acids derived from lipolysis of adipose stores and from TAG-derived lipoproteins. Hepatic FAO converts fatty acids to acetyl-CoA, which condenses with oxaloacetate in the TCA cycle, whose electrons are used in the electron transport chain to generate high-energy phosphates. During states of high fatty acid mitochondrial delivery, most FAO-derived acetyl-CoA is diverted from the TCA cycle to ketogenesis, generating acetoacetate (AcAc) and b-hydroxybutyrate (bOHB). Ketogenesis is particularly stimulated during low insulin states [24] . Liver abundantly expresses the key ketogenic enzyme, mitochondrial 3-hydroxy-3-methylglutaryl (HMG)-CoA synthase, which is activated by Sirtuin 3-mediated deacetylation, and whose gene HMGCS2 is negatively regulated through transcriptional mechanisms downstream of insulin signaling [25, 26] . Because hepatic mitochondria lack the enzyme necessary for oxidizing ketone bodies, ketones are secreted and delivered to heart, skeletal muscle, and brain, which abundantly express the mitochondrial matrix enzyme succinyl-CoA:3-oxoacid-CoA transferase (SCOT, encoded by OXCT1), which is required to convert ketone bodies to acetyl-CoA for terminal oxidation in the TCA cycle [27] . Thus, hepatic ketogenesis helps maintain TCA cycle homeostasis, prevents the accumulation of incompletely oxidized fatty acid intermediates, maintains hepatic redox balance, and supplies extrahepatic organs with energy substrates in glucose-limiting states that include fasting, poorly controlled diabetes, and during adherence to low-carbohydrate, high-fat ketogenic diets. Although individuals with NAFLD have also been reported to exhibit higher circulating ketone concentrations, likely due to increased rates of FAO, bOHB turnover rates are not increased in individuals with NAFLD [12
&&
]. Increased TCA flux in NAFLD livers may partially explain normal bOHB turnover rates, but prospective roles for variation of ketolytic flux through SCOT, and of AcAc turnover, remain to be determined.
Ketogenic diets are actively used for weight loss and anticonvulsant therapy, and are intensively studied as potential adjunctive therapy for brain cancers and neurodegenerative diseases including Parkinson's and Alzheimer's diseases [28] [29] [30] [31] [32] . In humans, diets with caloric contents of up to 75-80% fat and 15% or more protein are commonly used for management of seizure disorders (e.g., 4 : 1 prescriptions, in which calories are derived from four parts fat, and one part protein plus carbohydrate), and Atkins diets for weight loss typically consist of 60-70% fat and up to 30% protein. Anticonvulsant benefits of ketogenic diets persist for 6 years or more in patients following discontinuation [33] . Although the mechanism(s) of ketogenic diet's salutary neurological effects have not been fully elucidated, observations from a number of genetic and acquired epilepsy models in rodents have implicated a dysregulation of the mammalian target of rapamycin pathway, neuron-astrocyte crosstalk in neurotransmitter metabolism, and manipulation of hypothalamic hormone signaling [32] [33] [34] [35] [36] .
Not all patients can tolerate ketogenic diet regimens, which can be unpalatable, and scrupulous attention to micronutrient content and overall caloric needs is required. Hyperuricemia, hypocalcemia, hypomagnesemia, nephrolithiasis, and, of course, ketoacidosis can result from ketogenic diets. Rare studies implicate the ketogenic diet in cardiac complications, including cardiomyopathy, prolonged QTc interval and torsades de pointes arrhythmias [8] . However, this response appears to be sporadic, as a systemic analysis of 27 children adhering to prescribed ketogenic diet for treatment of refractory epilepsy revealed no changes in QTc interval over 12 months [37] . Nonetheless, these data underscore the importance of careful patient monitoring, and perhaps expansion of monitoring guidelines.
KETOGENIC DIETS AND NONALCOHOLIC FATTY LIVER DISEASE IN HUMANS AND RODENTS
Promotion of weight loss is often recommended to obese patients with hepatic steatosis, and is frequently achieved through a reduction of caloric intake. Although intensively studied, the efficacy and safety of shifts in macronutrient content still remain to be determined in a systematic mannerparticularly with respect to effects on NAFLD. A small clinical trial of 18 patients used MRS to measure change in IHTG following 2 weeks of either a calorie-restricted diet, or a carbohydrate-restricted diet that was not calorie restricted, and found that patients in the carbohydrate-restricted arm exhibited a more profound IHTG reduction, without any difference in overall weight loss, compared with the calorie restricted arm [38 && ]. A recent 2-year multicenter trial that included over 300 patients enrolled in a comprehensive lifestyle modification regimen observed similar weight loss achieved by adherence to low-fat versus low-carbohydrate diets. The low-carbohydrate diet group exhibited superior high-density lipoprotein (HDL) cholesterol profiles [39 && ]. As expected, urinary ketosis was markedly more common in the low-carbohydrate group, but the influence of these regimens on IHTG was not presented. Comparing low-carbohydrate to reduced calorie or low-fat diets in clinical trials to date, systemic glucose homeostasis has not systematically differed.
Ketogenic diets have been extensively studied in rodents. Using a micronutrient supplemented ketogenic diet (Diet #F3666, Bio-Serv, Frenchtown, New Jersey, USA) very high in fat (93.3% kcal), very low in carbohydrate (1.8%), and also reduced in protein (4.7%), Meratos-Flier and colleagues observed that mice lose weight, develop ketosis, and induce hepatic gene expression signatures that suggest reduced DNL and increased FAO [40] . To explore the relationships among ketogenic diet, IHTG, and NAFLD, Garbow et al. [41 && ] maintained C57BL/6J mice for 12 weeks on either Bio-Serv F3666 ketogenic diet; a high-fat (40% kcal) 'Western' diet also enriched in sucrose (40%); or a standard low-fat (13% kcal) polysaccharide-rich chow control diet. The ketogenic diet is reduced in protein content due to the fact that induction of ketosis in rodents requires restriction of not only carbohydrates but also protein [42] . Mice fed the ketogenic diet for 12 weeks were lean, euglycemic, ketotic, and hypoinsulinemic, but were glucose intolerant, and exhibited NAFLD. MRS revealed that ketogenic diet-fed mice accumulate hepatic lipid within 3 weeks after initiation of the diet, and the hepatic gene expression signature for DNL (encoded mediators of sterol regulatory element-binding protein (SREBP)-1c, fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC)-1, stearoyl-CoA desaturase (SCD)-1) was suppressed compared with livers of chow-fed controls. In contrast, mice fed the Western diet ultimately accumulate higher IHTG than ketogenic diet-fed animals, but do so much more slowly, and as expected due to the high sucrose content, induce mediators of DNL. Intriguingly, unlike steatotic livers of Western diet-fed mice, livers of ketogenic diet-fed mice developed hepatic endoplasmic reticulum (ER) stress, inflammation, macrophage accumulation, and hepatocellular injury, and only ketogenic diet-fed mice exhibited elevated serum ALT concentrations. A number of nonmutually exclusive mechanisms may account for the murine hepatic phenotypes observed with this ketogenic diet. First is the prospective influence of choline and methionine deficiencies. While choline-replete rodent diets are supplemented to contain approximately 2.5 g/kg, Bio-Serv F3666 ketogenic diet is not supplemented, and therefore contains only 200-300 mg/kg naturally derived from the fat sources. Methionine content in this ketogenic diet, derived from casein, is also reduced, at 2.2 g/kg, whereas methionine-replete diets contain approximately 4 g/kg. A second prospective contributor to the NAFLD signatures in ketogenic diet-fed mice is overall reduction of protein: classical studies indicate that diets containing less than 14% protein retard normal growth, reproduction, and lactation in mice [43] . A third prospective influence is cellular injury, effected by ER stress-inducing membrane remodeling in periportal hepatocytes that receive more fat than can be oxidized or exported via VLDL secretion. Fourth, ceramide production within macrophages or hepatocytes, favored by high intracellular concentrations of saturated fatty acids, may also trigger the inflammasome, whose biomarkers were selectively elevated in livers of ketogenic diet-fed mice. Finally, splice variants of the insulinsensitizing nuclear receptor transcription factor peroxisome proliferator-activated receptor (PPAR)-g may exhibit distinct activities in different steatotic contexts. While the 'adipocyte' isoform form, PPARg2, was induced in livers by a Western diet, the 'macrophage' isoform PPARg1 was selectively induced in livers of ketogenic diet-fed mice.
Hepatic fibroblast growth factor 21 (FGF21) has emerged as a key regulator of hepatic metabolism, glucose, and fatty acid oxidative flux, and insulin sensitivity [44, 45] . Ketogenic diet feeding of Fgf21 À/À mice leads to weight gain, reduced ketosis, and hepatic steatosis relative to ketogenic diet-fed wild-type controls in 2 weeks, consistent with impaired ability of the liver to oxidize fatty acids in the absence of FGF21 [46] . Indeed, serum FGF21 concentrations are elevated in patients with diagnosed NAFLD, and obesity is an FGF21-resistant state [47, 48] . Fgf21 mRNA is markedly induced in livers of mice fed either ketogenic diet or a Western diet for 12 weeks [41 && ].
steatosis, cellular injury, and macrophage accumulation. However, indices of insulin resistance were not observed [41 && ]. Compared with chow-fed and Western diet-fed mice, ketogenic diet-fed mice exhibited reduced homeostatic model assessment of insulin resistance values, normal insulin-induced hepatic and skeletal muscle Akt phosphorylation, and increased whole-body glucose disposal by insulin tolerance test (ITT). Badman et al. [49] also observed insulin-sensitizing effects of 7 weeks of this ketogenic diet on obese leptin-deficient ob/ob mice: while neither obesity nor IHTG of ob/ob mice was ameliorated by feeding the ketogenic diet, the diet did improve glucose intolerance, hyperinsulinema, and glucose disposal by ITT. In apparent contradistinction, Shulman and colleagues observed a 350% increase in hepatic diacylglycerol content, protein kinase C (PKC)-e activation, and decreased insulin signaling at the level of insulin receptor substrate-2 tyrosine phosphorylation in wild-type mice fed this ketogenic diet for 5 weeks [50 & ]. Furthermore, hyperinsulinemiceuglycemic clamp studies revealed impairment of insulin-mediated suppression of glucose production by livers of ketogenic diet-fed wild-type mice. The apparent discordance of these findings by this latter group of investigators may be explained by two factors. First, liver and muscle may exhibit distinct phenotypes in ketogenic diet-fed mice. Although ketogenic diet-induced hepatic insulin resistance was observed in the clamp studies, impairment of insulin-stimulated peripheral glucose disposal in ketogenic diet-fed mice was much more subtle. Therefore, enhanced systemic response to insulin (by ITT) in ketogenic diet-fed mice likely reflects augmentation of insulin-mediated peripheral glucose disposal, relative to the chow group, that overrides any prospective impairment of insulinmediated suppression of hepatic glucose production that may exist in ketogenic diet-fed mice. Second, hyperinsulinemic-euglycemic clamp studies in mice have proven controversial due to variations of methods that normalize hepatic glucose output, insulin dosing regimens among investigators, and responses of humans versus anesthetized miceespecially those fed a ketogenic diet, which creates an unusual hypoinsulinemic-euglycemic metabolic state, accompanied by markedly increased IHTG [51, 52] . Important conclusions emerge from the heretofore-performed studies of ketogenic diet-fed mice. First, the relevance of the NAFLD signatures in ketogenic diet-fed mice to human NAFLD pathophysiology remains to be determined. Although it is intriguing that increased IHTG, inflammation, and ER stress may be dissociable from systemic insulin resistance, this constellation of findings is not unique in that it has been observed with MCD diets in rodents, which have also been criticized as less relevant to human NAFLD. Second, the combination of hypoinsulinemia, euglycemia, glucose intolerance, and enhanced insulin responsiveness by ITT all suggest that glucose-stimulated insulin secretion by pancreatic b-cells could be abnormal in ketogenic diet-fed mice. Finally, although the use of this low-protein, very high-fat, low-carbohydrate diet is not directly relevant to macronutrient distributions ingested by humans, it does provide an important foundation to elucidate the range of metabolic responses that occur in states relevant to human physiology.
CONCLUSION
Ketogenic diets are prescribed with increasing frequency for NAFLD, obesity, and neurological disease, and although they have beneficial attributes, their metabolic effects are not yet completely understood, and patient responses to these diets can be variable. Recent studies have provided insight into the contribution of macronutrient content on liver health and demonstrate the influences of shifting macronutrient class distributions. Therefore, future studies of low-carbohydrate diets in rodents and humans must take into consideration additional factors including the effects of low overall protein, choline, and methionine content, and the saturation and length of dietary fatty acids. Achieving macronutrient and micronutrient balance will be essential to developing efficacious diets that promote weight loss while maintaining systemic health.
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